Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date.

Abstract

The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab).

• Authors: M Galluzzo, S D'Adamio, A Massaro, A Piccolo, L Bianchi, M Talamonti
• Journal: Clinical, cosmetic and investigational dermatology (Clin Cosmet Investig Dermatol) Vol. 12 Pg. 311-321 ( 2019) ISSN: 1178-7015 [Print] New Zealand
• PMID: 31118733 (Publication Type: Journal Article)